BANKRUPTCY PLAYS

[I Like Bottom Fishing]

Oscient Pharmaceuticals Corporation (pinksheets:OSCIQ) Stock Symbol:Company Profile:
http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ
Knobias MEMBERS get: Quotes | Charts | Technical Analysis | Quick Profiles | EDGAR Filings | News & Alerts | TearSheet Profiles | Historical Statistics | Insider Transactions | Institutional Holdings | ...and Much More
http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

Last Trade: 0.056 Change: -0.003 ( -4.310 %)
Previous Close: 0.058 Today's Open: 0.060
# of Trades: 39 Volume: 427,353
Avg. # of Trades: 55 Avg. Daily Volume: 1,032,610

Bid: N/A Bid Size: N/A
Ask: N/A Ask Size: N/A
Day High: 0.060 Day Low: 0.055
52 Week High: 1.170 52 Week Low: 0.016
Market Cap: 2.16M Dividend: N/A
EPS: N/A P/E Ratio: N/A

6 Month Chart

RAiDAR alerts Learn More About RAiDAR-LT
09/29/2009 (22:58 ET) INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN - AsiaPulse Pte. Ltd
09/09/2009 (07:10 ET) Cornerstone Wins Factive Rights - Zacks.com
09/05/2009 (13:07 ET) Cornerstone wins approval to acquire rights to Oscient's antibiotic drug - Datamonitor
09/03/2009 (08:01 ET) Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R) - PR Newswire
08/10/2009 (09:50 ET) OSCIQ: New 52-Wk Low @ $0.020 dn 20% - Knobias
08/07/2009 (12:40 ET) OSCIQ: New 52-Wk Low @ $0.025 dn 9.26% - Knobias
08/06/2009 (15:10 ET) OSCIQ: New 52-Wk Low @ $0.026 dn 13.33% - Knobias
07/31/2009 (12:00 ET) OSCIQ: New 52-Wk Low @ $0.028 dn 12.5% - Knobias
07/30/2009 (10:10 ET) OSCIQ: New 52-Wk Low @ $0.029 dn 6.35% - Knobias
07/28/2009 (09:55 ET) OSCIQ: Filed New Form 25-NSE - Edgar
07/22/2009 (03:12 ET) The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health - PRWeb.com
07/20/2009 (11:40 ET) OSCI: Volume Spike; 43% > 20-adsv, Stock +53.25% - Knobias
07/20/2009 (10:10 ET) OSCI: New 52-Wk Low @ $0.035 dn 9.09% - Knobias
07/17/2009 (12:10 ET) OSCI: New 52-Wk Low @ $0.041 dn 16.12% - Knobias
07/17/2009 (08:20 ET) AnalystChoice.com Brings You the Best Complimentary Research Report on DLTR, PMCS, CMCSA, DDUP, CREE and OSCI - Market Wire
07/15/2009 (08:51 ET) Oscient Pharmaceuticals files for Chapter 11 bankruptcy protection - Datamonitor
07/15/2009 (07:10 ET) Cornerstone Buys OSCI Antibiotic - Zacks.com
07/14/2009 (23:07 ET) Oscient Pharmaceuticals Files for Chapter 11 Relief - Close-Up Media
07/14/2009 (13:16 ET) Cornerstone Therapeutics signs asset purchase agreement with Oscient - Datamonitor
07/14/2009 (07:40 ET) Cornerstone Therapeutics To Buy Factive Rights - Investrend
07/13/2009 (17:51 ET) OSCI: Files Chapter 11; To Sale Assets of FACTIVE to Cornerstone Therapeutics - Knobias
07/13/2009 (17:35 ET) Cornerstone Therapeutics Signs Definitive Asset Purchase Agreement to Acquire Commercial Rights to the Antibiotic Factive(R) - PR Newswire
07/13/2009 (17:12 ET) OSCI: Filed New Form 8-K, Material Event Disclosure - Edgar
07/13/2009 (17:05 ET) Oscient Pharmaceuticals Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code - Business Wire

company profile
A commercial-stage pharmaceutical company, which markets products to primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States. ... MORE INFO

CONTACT: Steven M. Rauscher (CEO)
Oscient Pharmaceuticals Corporation
1000 Winter Street
Suite 2200
Waltham, MA 02451
P: [phone]
P: [phone] / [phone]
F: [phone]
Company Home Page | Email

Industry: Drugs
SIC: 2834
Employees: 316
Locations: 0

State of Inc: MASSACHUSETTS
Development Stage? N Transfer Agent:
Computershare Investor Services
Golden, CO 80401

Investor Relations:
Company Authorized Shares: 174,375,000
Source: 10-Q ( 09/30/2006 )

Outstanding Shares: 39,003,978
Source: MGFS ( 03/20/2009 )

Fiscal Year End: December 31

MANAGEMENT & INSIDERS:

Need More Stock Research? Subscribe NOW!!!

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.


INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.